9-Me-BC
A synthetic β-carboline alkaloid studied preclinically for promoting dopaminergic neuron growth and boosting dopamine synthesis.
9-Methyl-β-carboline (9-MBC) is a synthetic β-carboline alkaloid that has drawn interest in the nootropic community for its reported ability to promote dopaminergic neuron growth, increase dopamine synthesis enzymes, and provide neuroprotection against neurotoxins. It is one of the few compounds with preclinical evidence for actual dopaminergic neurogenesis rather than merely modulating dopamine release or reuptake. Research fields explored include Parkinson's disease, dopaminergic neurodegeneration, depression, and general cognitive enhancement.
Class
Synthetic β-carboline alkaloid (small-molecule nootropic)
Routes
Oral, Sublingual
Category
Cognitive & Nootropic
Researched benefits
What it's studied for
Enhanced dopamine levels
Preclinical work indicates 9-MBC increases dopamine synthesis enzymes and raises dopamine levels, in part by enhancing dopamine transporter expression, positioning it as a dopaminergic compound.
Dopaminergic neurogenesis
9-MBC is one of the few compounds with preclinical evidence for actual growth of dopaminergic neurons, rather than only modulating dopamine release or reuptake.
Neuroprotection
It has shown neuroprotective effects against neurotoxins in preclinical models, a rationale for its investigation in dopaminergic neurodegeneration and Parkinson's disease.
Increased motivation and drive
Users report increased motivation and drive, consistent with its dopaminergic mechanism, along with improved focus and energy.
Improved focus and energy
The compound is used in the nootropic community for cognitive enhancement, with reported improvements in focus and subjective energy.
Mechanism
How it works
9-Me-BC acts as a dopaminergic and serotonergic compound. It functions both as a β-carboline alkaloid and as a phosphodiesterase inhibitor, a combination that supports elevated intracellular signaling and dopaminergic activity.
Mechanistically, it enhances dopamine transporter expression and increases dopamine levels, while also raising the activity of dopamine synthesis enzymes. Rather than simply promoting release or blocking reuptake, preclinical data suggest it can drive the growth of dopaminergic neurons (neurogenesis).
Beyond the dopaminergic system, 9-MBC has been associated with neuroprotection against neurotoxins and with UV-stimulated melanogenesis. As a β-carboline it can also interact with monoamine oxidase, which underlies cautions around serotonergic drugs and tyramine-rich foods.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Standard
- Dose
- 5 mg - 30 mg daily
- Frequency
- Once daily
- Timing
- Earlier in the day
- Duration
- Cycled use
- Route
- Oral or sublingual
Community-reported range. Avoid late-day dosing due to stimulation and insomnia risk. Because 9-MBC is a photosensitizer, avoid direct sun/UV exposure for hours after dosing.
- Reported dose range is 5 mg to 30 mg daily by oral or sublingual route.
- Dose late-day dosing should be avoided as it can cause insomnia.
- As a photosensitizer, sun and UV exposure should be avoided on dosing days to reduce phototoxicity risk.
- Detailed tiered protocols (beginner/intermediate/advanced) and weight-based calculations were not available in the source.
Combinations
Stacking & blends
9-MBC + Bromantane
Dopaminergic focus and drive
Both are dopaminergic nootropics; the source lists this pairing under 'Caution,' so it should be approached carefully rather than assumed synergistic.
9-MBC + Sulbutiamine
Motivation and cognitive energy
Sulbutiamine also modulates dopaminergic tone; the source flags this combination as 'Caution.'
9-MBC + Phenylpiracetam
Stimulation and focus
Phenylpiracetam is a stimulating racetam; combined with 9-MBC's dopaminergic action, the source marks this as 'Caution' for overstimulation.
Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Concurrent UV/sun exposure (phototoxic — can cause DNA damage)
- SSRI, SNRI, or MAOI use (serotonin syndrome risk)
- Concurrent MDMA or other serotonergic substances
- Tyramine-rich foods while using (MAO inhibition)
- Liver disease
- History of melanoma
- Pregnancy or breastfeeding
Do NOT combine 9-MBC with SSRIs, SNRIs, MAOIs, MDMA, or other serotonergic substances due to serotonin syndrome risk. Avoid tyramine-rich foods because of MAO inhibition, and avoid UV/sunlight exposure on dosing days due to phototoxicity.
FAQ
9-Me-BC — common questions
What is 9-Me-BC used for in research?
9-Methyl-β-carboline is a synthetic β-carboline alkaloid studied preclinically for promoting dopaminergic neuron growth, increasing dopamine synthesis enzymes, and neuroprotection against neurotoxins. It is notable as one of the few compounds with preclinical evidence for actual dopaminergic neurogenesis rather than just release or reuptake modulation.
What research fields is 9-Me-BC being explored in?
Reported research fields include Parkinson's disease, dopaminergic neurodegeneration, depression, and cognitive enhancement.
What dose of 9-Me-BC is typically used?
The reported dose range is 5 mg to 30 mg daily, taken orally or sublingually. It is best dosed earlier in the day to avoid insomnia.
Why should I avoid sunlight when using 9-Me-BC?
9-MBC is a photosensitizer and can be phototoxic, potentially causing DNA damage with UV exposure. Avoid direct sun for hours after dosing and ideally on dosing days.
What should 9-Me-BC not be combined with?
It should not be combined with SSRIs, SNRIs, MAOIs, MDMA, or other serotonergic substances because of serotonin syndrome risk. Tyramine-rich foods should also be avoided due to MAO inhibition, and caution is advised with stimulating nootropics like Bromantane, Sulbutiamine, and Phenylpiracetam.
What forms does 9-Me-BC come in?
9-Me-BC is available in capsule form.
Is 9-Me-BC approved for human use?
No. It remains a preclinical, unapproved research compound with no regulatory approval, and it has not been evaluated in human clinical trials.
